ICAAC 2006: Index of Coverage

Now Live: Breaking Research From AIDS 2008: Podcasts, Interviews, Videos & More >>

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

ICAAC 2006: Index of Coverage

Antiretrovirals in Development

MK-0518 Demonstrates Potent Efficacy in Patients With Triple-Class-Resistant Virus: 24-Week Results (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
The Integrase Inhibitor MK-0518 Demonstrates a Favorable Lipid Profile (September 27, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy

Basic Science

The Role of the FUT2 Gene in HIV Non-Progression (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy

Complications of HIV/HAART

Comparing the Effects of Rosiglitazone, Pravastatin, Recombinant Human Growth Hormone and Combinations Thereof on HIV-Associated Lipodystrophy (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Recombinant Human Growth Hormone Produces Pronounced and Durable Reductions in Visceral Adipose Tissue (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
The Effect of Tenofovir and Other Antiretroviral Therapy on Renal Tubular Cells in Vitro (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy

First-Line Antiretroviral Treatment

The Once-Daily Abacavir/Lamivudine Co-Formulation Proves Its Mettle by Being Both Safe and Effective (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Fosamprenavir Efficacy and Safety on Par With Other PIs, With No Gender-Based Differences (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Older People Diagnosed With More Advanced Disease Compared to Younger People (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Risk for AIDS-Defining Events Is Greater Among Antiretroviral-Naive Patients Who Don't Achieve CD4+ Cell Count Above 200 on Treatment (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Zidovudine/Lamivudine/Abacavir May Be Appropriate for Some Treatment-Naive Patients With Low-Baseline Viral Loads (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy

HIV Drug Resistance

How the HIV-1 Reverse Transcriptase Mutations K65R, M184V and K65R + M184V Produce Resistance to NRTIs (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Phenotypic Clinical Cutoffs for Tipranavir/Ritonavir Defined Based on RESIST Data (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Rise in NRTI Mutations Is Associated With Rise in NNRTI, Protease Inhibitor Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy

HIV Prevention

Antiretroviral Drugs as Prevention Tools: PEP, PrEP and Prevention for Positives (September 27, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy

Treatment-Experienced Patients

Tipranavir/Ritonavir-Associated Hepatotoxicity Common, But Resolves Over Time (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Virologic Outcomes With Tipranavir + Ritonavir Prove to Be Durable Out to 96 Weeks in the RESIST Studies (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Whereas Other PIs Fail, Tipranavir Maintains High-Level Potency Against Key PI Resistance Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy

Treatment Strategies

COOL Study: The Ultimate Misnomer? (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Long-Term Lopinavir/Ritonavir Treatment and CD4+ Cell Responses (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
No Difference in HAART Response in Patients With X4-Using HIV (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Reducing the Dose of Lopinavir/Ritonavir Is Associated With Low-Level Viremia (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
An Overview of the Pathogenesis and Treatment of Primary HIV Infection (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Lower Adherence May Precede Viral Load "Blips" (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Strategic Use of Antiretroviral Therapy: What to Use and When? (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.